RLMD — Relmada Therapeutics, Inc.
Is RLMD overbought or oversold? Here is the current MarketMoodz read.
Relmada Therapeutics, Inc. (RLMD) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Biotechnology) last closed at $3.60. The rating moved from Neutral to Oversold on September 18, 2026.
- Public ratingOversold (as of October 3, 2026)
- Last close$3.60
- Last changeMoved from Neutral to Oversold on September 18, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
Relmada Therapeutics, Inc. (RLMD) is a small clinical-stage company whose near-term value is driven by discrete clinical and financing milestones. Absent fresh positive data or a partnering announcement, the stock is likely to trade with elevated volatility and sensitivity to sector-wide risk-off flows, Medicare pricing debate, and capital markets conditions. Potential upside depends on clear clinical readouts or non-dilutive financing; downside is dominated by trial setbacks, funding needs, and worsening payer pricing pressure.
Key factors
- Relmada Therapeutics, Inc. (RLMD) is a small-cap clinical-stage biopharma with outcomes tied to a narrow pipeline and milestone-driven valuation
- Market risk-off environment and cooling of healthcare IPO/biotech capital markets reduces near-term access to non-dilutive funding and heightens dilution risk
- Sector tailwinds from positive late-stage rare-disease biologic readthroughs that can lift investor appetite for specialty pharma stories if Relmada posts convincing clinical data
- Persistent macro/policy focus on drug pricing and Medicare negotiation increases pricing and access uncertainty for novel therapies
- Limited publicly available recent financial disclosure in the provided materials suggests cash runway and financing cadence are primary near-term drivers
- Low trading volumes and episodic news sensitivity typical of small-cap biotech increase volatility around any clinical, regulatory or partnering announcements
Risks
- Clinical trial failure or disappointing efficacy/safety readouts that would materially reduce valuation
- Need to raise capital in a risk-off funding environment, leading to dilution and share pressure
- Adverse regulatory decisions or slower-than-expected regulatory timelines
- Downward pricing pressure and reimbursement challenges from Medicare negotiation and payer cost-control measures
- Intensifying competition in adjacent therapeutic areas and potential for larger competitors to develop superior or more cost-effective alternatives
- Low liquidity and market sentiment swings driven by macro headlines (geopolitics, rate speculation) that can magnify share moves
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for RLMD — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.